The news: Novo Nordisk’s GLP-1 drug semaglutide failed to slow the progression of Alzheimer’s disease in new study results, dimming hopes that GLP-1s might be approved to treat the condition.

• Novo tested its oral GLP-1 Rybelsus, which is approved to treat type 2 diabetes, over two years, but will now discontinue those studies.
• The trials were closely watched by other GLP-1 makers as an indicator of whether the class could help Alzheimer’s patients.
• Novo’s stock dropped more than 12% upon the news, while shares of Biogen and Eli Lilly, the two drugmakers with FDA-approved Alzheimer's treatments, both rose.

Why it matters: GLP-1 drugs are being studied across a wide range of health conditions after gaining FDA approval to treat type 2 diabetes, obesity, cardiovascular disease risk, liver disease, and sleep apnea.

• Novo and Lilly are both considering GLP-1 studies as possible treatments for alcohol and drug addiction.
• Smaller studies evaluating GLP-1s for Parkinson’s disease and in cognitive impairment for major depression did not show positive results.

Implications for pharma: Novo’s Alzheimer’s results underscore the boundary of how far GLP-1s can stretch beyond metabolic diseases.

Alzheimer’s was always a high-risk target—Novo itself described the effort as a “lottery ticket”—so the readout is more a missed upside than a failure. Still, the results will shift industry expectations that GLP-1s could become near-term treatments in neurological conditions. For drugmakers, the news reinforces the need for a more focused pipeline strategy, optimizing and expanding in areas where GLP-1s are already validated, like weight management, cardiovascular risk reduction, and liver disease.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.